Dr. RAMI MANOCHAKIAN ( MAYO CLINIC ) : IMforte ( LURBINECTEDIN + ATEZOLIZUMAB ) OFRECE UN NUEVO PUNTO DE DEBATE PARA EL MANTENIMIENTO DEL SMALL CELL LUNG CANCER EXTENSIVE-STAGE , CON BENEFICIOS PARA "" ALGUNOS PACIENTES "" , PERO CON UNA TOXICIDAD NOTABLE .

LO VIENEN COMUNICANDO REPUTADOS ONCOLOG@S ESPECIALIZADOS EN EL TRATAMIENTO DE SMALL CELL LUNG CANCER DESDE LA CELEBRACIÓN DEL CONGRESO ASCO25 ... Y HOY TENEMOS UNA NUEVA COMUNICACIÓN POR PARTE DEL ONCOLOGO RAMI  MANOCHAKIAN ... :

 

Dr. Rami Manochakian is a thoracic medical Oncologist who joined Mayo Clinic in January 2017.

He earned his medical degree from the University of Aleppo in Syria.

He completed Internal Medicine residency and chief residency at the University at Buffalo, NY.

 He completed Hematology/Oncology fellowship and was a chief fellow at Case Western Reserve University, Cleveland, OH .